Drug Watch

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

In the phase 3b TOGETHER-PsO trial, ixekizumab plus tirzepatide led to significantly higher rates of complete skin clearance and ≥10% weight loss.

Investigators identified overlap between the blood immune profiles of patients with depression and inflammatory skin diseases, highlighting the Th2 axis as a potential treatment target.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

Advances in stem cells, exosomes, biomaterials, and RNA technologies are expanding therapeutic options beyond traditional wound-based remodeling.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

Aminex Therapeutics has initiated a trial evaluating AMXT 1501 and DFMO, with implications for dermatologists managing advanced melanoma.

Sagimet and Ascletis shared denifanstat's 52-week safety results plus sustained improvements, highlighting a once-daily oral FASN inhibitor for acne.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.